All Posts: mind
-
Nilotinib Appears Safe in Parkinson’s Trial; Drug Thought to Allow Dopamine Replenishment
WASHINGTON (December 16, 2019) — A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson’s disease finds that it is reasonably safe and well tolerated. Researchers also report finding an increase in dopamine, the chemical lost as a result of neuronal destruction, and a decrease in neurotoxic proteins in the brain among […]
Category: News Release
-
Maguire-Zeiss Named New Chair of Department of Neuroscience
(August 29, 2019) — Since joining Georgetown’s faculty in 2007, Kathy Maguire-Zeiss, PhD, has taken on many roles. In addition to being a professor of neuroscience, she directs the Interdisciplinary Program in Neuroscience (IPN), the Center for Neural Injury and Recovery, the master’s degree program in integrative neuroscience and the T32 Training Program in Neural […]
Category: GUMC Stories
-
Shedding Light on Lewy Body Disease
(May 30, 2019) — Though many people are familiar with Parkinson’s and Alzheimer’s diseases, fewer have heard of Lewy body dementia, a neurodegenerative disorder with similar symptoms. “I think more awareness needs to be out there because Lewy body disease is probably just as prevalent as Parkinson’s,” said Fernando Pagan, MD (M’96), professor of neurology […]
Category: GUMC Stories
-
Georgetown University Launches Clinical Trial for Lewy Body Dementia
MEDIA CONTACT:(for members of the press only) Karen Teberkm463@georgetown.edu PATIENT INFORMATION:Joy Arellanomja6@gunet.georgetown.edu WASHINGTON (May 30, 2019) — Georgetown University Medical Center announces the launch of the only known therapeutic (disease modifying) clinical trial for Lewy body dementia, a neurological disorder that affects a million people in the United States for which there are no approved […]
Category: News Release
-
Why Adults at Risk for Huntington’s Disease Choose Not to Learn if They Inherited Deadly Gene
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (May 16, 2019) — As many as 90 percent of individuals who have a parent with Huntington’s disease (HD) choose not to take a gene test that reveals if they will also develop the fatal disorder — and a new study details the reasons why. Understanding the “why” matters as new […]
Category: News Release
-
Impacted by Parkinson’s Disease, Three Couples Plan to Leave a Lasting Legacy to Support Research
(April 26, 2019) — When someone is diagnosed with an incurable, life-changing disease like Parkinson’s, they usually have many questions about how it will affect their life and what can be done to manage it. Unfortunately, many people who have Parkinson’s symptoms don’t get those answers until they are fortunate enough to see a doctor […]
Category: GUMC Stories
-
Georgetown’s Memory Disorders Program Marks 20th Year
(April 12, 2019) — When President Ronald Reagan announced in 1994 that he had Alzheimer’s disease, the man known as the “great communicator” tried his best to convey a sense of optimism. “I now begin the journey that will lead me into the sunset of my life. I know that for America there will always […]
Category: GUMC Stories
-
Training the Next Generation of Researchers in Movement Disorders
(February 8, 2019) — After she first developed a tremor in her right hand, years went by before Pam Cota was diagnosed with Parkinson’s disease by Fernando Pagan, MD (M’96, R’00), director of the MedStar Georgetown University Hospital Movement Disorders Clinic. The number of Parkinson’s disease patients expected to grow to 1.2 million by 2030, according […]
Category: GUMC Stories
-
Georgetown Physician Leads International Experts in Developing Treatment Guidelines for Huntington’s Disease Symptoms
(February 1, 2019) — A group of international experts in Huntington’s disease, led by Georgetown University Medical Center’s Karen Anderson, MD, has developed consensus guidelines for the clinical management of behavior symptoms caused by the incurable disease. Huntington’s disease is a fatal genetic disorder that impacts a person’s physical and mental abilities that is often accompanied […]
Category: GUMC Stories
-
Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases
Georgetown University today announces it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.
Category: News Release